Key Takeaways Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European ...

Peter Marks says the new health secretary’s team wants to show vaccines aren’t safe while promoting dangerous and unproven ...

Guggenheim lowered the firm’s price target on Sarepta (SRPT) to $112 from $150 and keeps a Buy rating on the shares. The firm, in its preview ...

Scotiabank analyst Louise Chen maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price reduced by Needham & Company LLC from $202.00 to $183.00 in a report published on Thursday,Benzinga reports. Needham & Company LLC ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

Sarepta Therapeutics, Inc. has a 12 month low of $54.26 and a 12 month high of $173.25. The company’s fifty day simple moving average is $96.95 and its 200-day simple moving average is $113.70.

CAMBRIDGE, Mass., April 04, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only ...